Lone Star Bio
Filter News
Found 16,206 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
ANDREWS MEDICINE AND CELLTEX THERAPEUTICS CORPORATION JOIN FORCES TO BRING CUTTING EDGE TECHNOLOGIES TO ATHLETIC INJURIES
10/4/2022
James R. "Jim" Andrews , MD, Chairman and CEO of Andrews Medicine of Pensacola, Florida , and David G. Eller , Chairman and CEO of Celltex Therapeutics Corporation of Houston, Texas, announced today that together they will form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries.
-
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
10/4/2022
Aeglea BioTherapeutics, Inc. today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystin is underway.
-
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
10/4/2022
Bellicum Pharmaceuticals, Inc. today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.
-
Plus Therapeutics to Share Data in Oral Presentations from Ongoing ReSPECT™ Clinical Trials at the 35th Annual Congress of the European Association of Nuclear Medicine
10/4/2022
Plus Therapeutics, Inc. today announced it will present data from two ongoing clinical trials evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome ( 186 RNL), in recurrent glioblastoma and leptomeningeal metastases at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM), being held October 15-19, 2022 in Barcelona, Spain.
-
Biopharma companies are expanding beyond the traditional confines of Massachusetts and California with hubs forming – most notably – in the South and Southeast.
-
Clinical Research Associates are almost always in high demand. Use these tips to create the best clinical research resume or CV to land your dream job.
-
CORRECTING and REPLACING NanOlogy Publishes Review Article of Preclinical and Clinical Research Supporting LSAM-DTX
10/3/2022
NanOlogy LLC, a clinical-stage interventional oncology drug company, announced that a review article of preclinical and clinical research supporting its investigational drug, large surface area microparticle docetaxel, has been published in Drug Delivery and Translational Research.
-
MD Anderson and ARTIDIS Announce Strategic Alliance to Advance Nanomechanical Technology Platform for Optimizing Cancer Treatment
10/3/2022
ARTIDIS AG and The University of Texas MD Anderson Cancer Center announced a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.
-
Hanger, Inc. Completes Acquisition by Patient Square Capital
10/3/2022
Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced the completion of its previously announced transaction to be acquired by Patient Square Capital, a leading dedicated health care investment firm, in an all-cash transaction.
-
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 03, 2022
10/3/2022
Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options.
-
Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors
10/3/2022
Gradalis, Inc. announced a peer-reviewed publication in Clinical Medicine Insights: Oncology demonstrating positive results from a pilot study investigating Vigil® in combination with a PD-L1 checkpoint inhibitor, durvalumab, in patients with advanced triple negative breast cancer or recurrent/refractory ovarian cancer.
-
McDonough to lead SwRI’s Chemistry and Chemical Engineering Division
10/3/2022
SwRI’s multidisciplinary staff conducts R&D for government, industry clients worldwide Dr. Joe McDonough has been named vice president of Southwest Research Institute’s Chemistry and Chemical Engineering Division.
-
New Analysis of SOLOIST-WHF Trial Underscores Sotagliflozin’s Effect on Reducing Recurrent Heart Failure Events
10/2/2022
Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes trial of sotagliflozin, an investigational dual SGLT1 and SGLT2 inhibitor, was presented at the Heart Failure Society of America Annual Scientific Meeting 2022.
-
TEXAS-DEVELOPED PATENT-FREE COVID-19 VACCINE TECHNOLOGY RECEIVES EMERGENCY USE AUTHORIZATION IN INDONESIA
9/30/2022
PT Bio Farma , the holding company for state-owned pharmaceutical companies in Indonesia , is ready to produce 20 million doses of the IndoVac COVID-19 vaccine this year and 100 million doses by 2024.
-
Hanger, Inc. Stockholders Approve Acquisition by Patient Square Capital
9/30/2022
Hanger, Inc., a leading provider of orthotic and prosthetic patient care services and solutions, announced that its stockholders approved at a special meeting the acquisition of Hanger by Patient Square Capital, a leading dedicated health care investment firm.
-
Nanoscope Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference
9/30/2022
Nanoscope Therapeutics Inc. announced that management will present at Chardan's 6th Annual Genetic Medicines Conference on Monday, October 3, 2022, in New York.
-
Natera Announces 2025 ESG Goals with Publication of 2021 Report
9/29/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity and improved access to health care.
-
Maxwell Biosciences Announces In Vivo and In Vitro Data on CLAROMER™ Platform’s Ability to Treat and Prevent SARS-CoV-2 and Other Respiratory Viruses at OPTIONS XI Conference
9/29/2022
Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced data on its CLAROMER drug discovery platform’s treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of pre-clinical in vitro and in vivo studies.
-
Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022
9/29/2022
Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced new product launches in the U.S. as well as activities taking place at the upcoming American Academy of Ophthalmology 2022 annual meeting in Chicago.